IN2015DN01706A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN01706A IN2015DN01706A IN1706DEN2015A IN2015DN01706A IN 2015DN01706 A IN2015DN01706 A IN 2015DN01706A IN 1706DEN2015 A IN1706DEN2015 A IN 1706DEN2015A IN 2015DN01706 A IN2015DN01706 A IN 2015DN01706A
- Authority
- IN
- India
- Prior art keywords
- achei
- increasing
- pharmaceutical composition
- high dose
- relates
- Prior art date
Links
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 2
- 239000002111 antiemetic agent Substances 0.000 abstract 2
- 229940125683 antiemetic agent Drugs 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 229940015042 glycopyrrolate Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 229960003510 propiverine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960003855 solifenacin Drugs 0.000 abstract 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 abstract 1
- 229960001491 trospium Drugs 0.000 abstract 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697039P | 2012-09-05 | 2012-09-05 | |
| US201261697069P | 2012-09-05 | 2012-09-05 | |
| US201261696978P | 2012-09-05 | 2012-09-05 | |
| US201261697021P | 2012-09-05 | 2012-09-05 | |
| PCT/US2013/058172 WO2014039627A1 (en) | 2012-09-05 | 2013-09-05 | Anticholinergic neuroprotective composition and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01706A true IN2015DN01706A (enExample) | 2015-05-22 |
Family
ID=50237591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1706DEN2015 IN2015DN01706A (enExample) | 2012-09-05 | 2013-09-05 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9561218B2 (enExample) |
| EP (2) | EP4035668A1 (enExample) |
| JP (4) | JP2015531346A (enExample) |
| KR (2) | KR20200065113A (enExample) |
| CN (1) | CN104768540A (enExample) |
| AU (1) | AU2013312749B2 (enExample) |
| BR (3) | BR122016020433A2 (enExample) |
| CA (1) | CA2882407C (enExample) |
| EA (1) | EA038489B1 (enExample) |
| HK (1) | HK1210947A1 (enExample) |
| IL (3) | IL237176B (enExample) |
| IN (1) | IN2015DN01706A (enExample) |
| MX (2) | MX378091B (enExample) |
| WO (1) | WO2014039627A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969402B2 (en) * | 2006-11-15 | 2015-03-03 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| ES2742728T3 (es) | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| JP6345665B2 (ja) * | 2012-08-09 | 2018-06-20 | チェイス・ファーマスーティカルズ・コーポレーション | ピペリジニウム第四級塩類 |
| MX378091B (es) * | 2012-09-05 | 2025-03-10 | Chase Pharmaceuticals Corp | Composicion neuroprotectora anticolinergica y metodos. |
| WO2016112263A1 (en) * | 2015-01-09 | 2016-07-14 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
| US10307409B2 (en) | 2015-03-06 | 2019-06-04 | Chase Pharmaceuticals Corporation | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system |
| US10596139B2 (en) | 2015-03-06 | 2020-03-24 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system muscarinic agonist combination |
| US20180360845A1 (en) * | 2015-07-20 | 2018-12-20 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| WO2017044693A1 (en) * | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| EP3347012A4 (en) * | 2015-09-11 | 2019-04-17 | Chase Pharmaceuticals Corporation | MUSCARIN COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDER OF THE CENTRAL NERVOUS SYSTEM |
| US10357487B2 (en) * | 2015-12-03 | 2019-07-23 | Sidney J. Goldfarb | Combinations of acetylcholinesterase inhibitors and muscarinic agonists and methods of use thereof |
| WO2017147104A1 (en) * | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combinations |
| US20190269627A1 (en) * | 2016-10-28 | 2019-09-05 | Chase Pharmaceuticals Corporation | Memantine combinations and use |
| EP3589369A4 (en) | 2017-01-09 | 2020-03-18 | DAS-MG, Inc. | USE AND COMPOSITION FOR TREATING SEVERE MYASTHENIA AND OTHER MYASTHENIC SYNDROMES |
| WO2018140412A1 (en) * | 2017-01-24 | 2018-08-02 | Gt Biopharma, Inc. | Neostigmine combination and compositions |
| JP7557939B2 (ja) * | 2017-03-27 | 2024-09-30 | チェイス セラピューティクス コーポレイション | シヌクレイノパチーを処置するための組成物および方法 |
| CN115581696A (zh) | 2018-09-28 | 2023-01-10 | 卡鲁娜治疗学有限公司 | 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 |
| US12112463B2 (en) | 2020-09-14 | 2024-10-08 | City University Of Hong Kong | Method, device and computer readable medium for intrinsic popularity evaluation and content compression based thereon |
| US11759451B2 (en) | 2020-09-15 | 2023-09-19 | City University Of Hong Kong | Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury |
| US12109202B2 (en) * | 2021-01-29 | 2024-10-08 | Qaam Pharmaceuticals, Llc | Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders |
| US20220304946A1 (en) * | 2021-03-28 | 2022-09-29 | Muhammad Imran Khan | Trans-anethole ((e)-1-methoxy-4- (1-propenyl) benzene), a new and potent inhibitor of prolyl endopeptidase |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| US3480626A (en) | 1967-05-18 | 1969-11-25 | Chem Fab Dr R Pfleger | Certain azoniaspironortropine derivatives |
| GB1204580A (en) | 1968-10-05 | 1970-09-09 | Aspro Nicholas Ltd | Pharmaceutical dosage forms |
| US3576388A (en) | 1968-12-05 | 1971-04-27 | Stauffer Wacker Silicone Corp | Electrical cable |
| DD106643A1 (enExample) | 1973-07-12 | 1974-06-20 | ||
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| GB9423588D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| EP0949920B1 (en) | 1997-07-09 | 2005-12-07 | Axonyx | Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| EP0976404A3 (en) | 1998-07-30 | 2001-06-27 | Pfizer Products Inc. | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal |
| DE69923200T2 (de) | 1998-10-01 | 2005-12-22 | Novartis Ag | Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe |
| CN1285348A (zh) | 1999-08-20 | 2001-02-28 | 广东康美药业股份有限公司 | 盐酸丙哌维林合成工艺 |
| IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
| JP2004529117A (ja) | 2001-02-08 | 2004-09-24 | シェーリング コーポレイション | 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用 |
| US7427280B2 (en) | 2002-09-06 | 2008-09-23 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues |
| CN1520818A (zh) | 2003-02-09 | 2004-08-18 | 山东绿叶天然药物研究开发有限公司 | 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物 |
| KR100510788B1 (ko) | 2003-07-22 | 2005-08-26 | 동방에프티엘 주식회사 | 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법 |
| KR100500760B1 (ko) | 2003-07-22 | 2005-07-14 | 동방에프티엘 주식회사 | 염산 프로피베린의 제조방법 |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| US7399778B2 (en) | 2004-01-16 | 2008-07-15 | Wyeth | Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole |
| AR051950A1 (es) | 2004-11-10 | 2007-02-21 | Osmotica Pharmaceutical Argent | Comprimido multicapa con capas que se separan |
| JP2008534480A (ja) * | 2005-03-24 | 2008-08-28 | ソーセイ アールアンドディ リミテッド | グリコピロニウム塩およびそれらの治療的使用 |
| US7390816B2 (en) | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| US20070224259A1 (en) | 2005-09-21 | 2007-09-27 | Gupta Anil K | Anti-inflammatory pharmaceutical composition |
| WO2007047010A2 (en) * | 2005-10-20 | 2007-04-26 | Indevus Pharmaceuticals, Inc. | Anti-emetic uses of cannabinoid analogs |
| US20070099988A1 (en) * | 2005-10-31 | 2007-05-03 | Indevus Pharmaceuticals, Inc. | Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids |
| JP2008535931A (ja) | 2005-12-21 | 2008-09-04 | テバ ファーマシューティカル インダストリーズ リミティド | ソリフェナシンの調製方法 |
| MX2008013539A (es) | 2006-04-21 | 2008-10-29 | Wyeth Corp | Produccion de intermediarios de amino alcohol quiralmente puros, derivados de los mismos, y usos de los mismos. |
| EP2037899B1 (en) | 2006-07-07 | 2011-03-30 | Aarhus Universitet | Nanoparticles for nucleic acid delivery |
| US8097633B2 (en) | 2006-11-15 | 2012-01-17 | Rich Steven A | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium |
| MX2010010460A (es) * | 2008-03-27 | 2010-12-15 | Chase Pharmaceuticals Corp | Uso y composicion para tratar la demencia. |
| US20110201597A1 (en) | 2008-03-27 | 2011-08-18 | Chase Thomas N | Method and composition for treating alzheimer-type dementia |
| WO2009139002A2 (en) | 2008-05-12 | 2009-11-19 | Msn Laboratories Limited | An improved process for the preparation of solifenacin and its pharmaceutically acceptable salts thereof |
| EP2451809B1 (en) | 2009-07-09 | 2016-10-12 | KRKA, D.D., Novo Mesto | A process for the preparation and purification of solifenacin salts |
| ES2746480T3 (es) * | 2009-09-18 | 2020-03-06 | Chase Pharmaceuticals Corp | Combinación para tratar demencia de tipo Alzheimer |
| KR20120023059A (ko) | 2010-03-15 | 2012-03-12 | 라마크리시나 라메샤 안다가 | 프로피베린 염산염의 합성 |
| EP2554184B1 (en) * | 2010-03-31 | 2016-10-26 | ONO Pharmaceutical Co., Ltd. | Preventive and/or remedy for hand and foot syndrome |
| KR101149821B1 (ko) | 2010-04-05 | 2012-05-24 | 하나제약 주식회사 | 디페닐아세테이트 유도체의 새로운 제조방법 |
| WO2012001481A1 (en) | 2010-06-28 | 2012-01-05 | Aurobindo Pharma Limited | Novel process for the preparation of solifenacin succinate |
| CN102218063B (zh) | 2011-04-12 | 2013-03-13 | 贵州神奇制药有限公司 | 盐酸丙哌维林药物的制备方法和产品及其检测方法 |
| MX378091B (es) * | 2012-09-05 | 2025-03-10 | Chase Pharmaceuticals Corp | Composicion neuroprotectora anticolinergica y metodos. |
-
2013
- 2013-09-05 MX MX2015002864A patent/MX378091B/es unknown
- 2013-09-05 BR BR122016020433A patent/BR122016020433A2/pt not_active Application Discontinuation
- 2013-09-05 EP EP22162245.9A patent/EP4035668A1/en not_active Withdrawn
- 2013-09-05 BR BR112015004902A patent/BR112015004902A2/pt not_active Application Discontinuation
- 2013-09-05 CA CA2882407A patent/CA2882407C/en active Active
- 2013-09-05 JP JP2015531176A patent/JP2015531346A/ja active Pending
- 2013-09-05 EA EA201500293A patent/EA038489B1/ru unknown
- 2013-09-05 IN IN1706DEN2015 patent/IN2015DN01706A/en unknown
- 2013-09-05 CN CN201380057910.7A patent/CN104768540A/zh active Pending
- 2013-09-05 MX MX2020002113A patent/MX385976B/es unknown
- 2013-09-05 BR BR122016020434A patent/BR122016020434A2/pt not_active Application Discontinuation
- 2013-09-05 WO PCT/US2013/058172 patent/WO2014039627A1/en not_active Ceased
- 2013-09-05 KR KR1020207015718A patent/KR20200065113A/ko not_active Ceased
- 2013-09-05 KR KR1020157008875A patent/KR20150048888A/ko not_active Ceased
- 2013-09-05 AU AU2013312749A patent/AU2013312749B2/en not_active Ceased
- 2013-09-05 EP EP13836121.7A patent/EP2892514A4/en not_active Withdrawn
- 2013-09-05 HK HK15111735.0A patent/HK1210947A1/xx unknown
- 2013-09-05 US US14/426,022 patent/US9561218B2/en not_active Expired - Fee Related
-
2015
- 2015-02-10 IL IL237176A patent/IL237176B/en active IP Right Grant
-
2016
- 2016-12-13 US US15/377,344 patent/US9913836B2/en active Active
-
2018
- 2018-01-25 US US15/879,803 patent/US20190000826A1/en not_active Abandoned
- 2018-01-25 IL IL257150A patent/IL257150A/en unknown
- 2018-04-23 JP JP2018082454A patent/JP2018150314A/ja active Pending
-
2019
- 2019-06-20 US US16/446,706 patent/US20190365736A1/en not_active Abandoned
- 2019-08-08 IL IL268603A patent/IL268603B/en active IP Right Grant
-
2020
- 2020-03-06 JP JP2020038441A patent/JP2020105212A/ja active Pending
-
2021
- 2021-08-16 JP JP2021132146A patent/JP2021191759A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01706A (enExample) | ||
| EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| WO2014028597A3 (en) | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| NZ708593A (en) | Novel pyrazole derivative | |
| IN2014MN01755A (enExample) | ||
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| MX344177B (es) | Uso y composicion para tratar la demencia. | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| PH12013502677A1 (en) | Benzylamine derivatives as inhibitors of plasma kallikrein | |
| EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| WO2014028591A3 (en) | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MX2014003080A (es) | Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c. | |
| IN2015DN01156A (enExample) | ||
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| NZ706739A (en) | Substituted benzene compounds | |
| IN2014MN02658A (enExample) | ||
| IN2014DN10386A (enExample) | ||
| PH12014502757A1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| IN2014KN01075A (enExample) | ||
| IN2014MN01962A (enExample) | ||
| PH12013501393A1 (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| NZ603625A (en) | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate | |
| IN2013DN02555A (enExample) |